AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05229965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Study NCT05229965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol Codeine
Description: 14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
Study NCT05229965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol caféine
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Study NCT05021809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide intracanal medication application
Description: The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
Study NCT06152887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sooma Oy (tDCS), Helsinki, Finland
Description: Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
Study NCT06152887 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sooma Oy (Sham), Helsinki, Finland
Description: For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
Study NCT04007276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine tartrate ophthalmic solution 0.025%
Description: Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
Study NCT04007276 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sterile balanced saline solution
Description: Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
Study NCT05270603 — intervention group
Intervention type: OTHER
Intervention: ICARUS intraoperative adverse events calculator
Description: The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language.
Study NCT04906915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The efficacy of ketamine was assessed by calculating oxygen supply and consumption
Study NCT04354454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Participants will select a daily step goal and track their steps every day for 4.5 months.
Study NCT04354454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit + Game + Support from a Teammate
Description: Daily Fitbit tracking for 4.5 months, divided into 2 parts.~* 3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~* 1.5 month follow-up period with Fitbit and social support teammate only
Study NCT06052098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system
Description: Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
Study NCT06052098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system
Description: Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
Study NCT06311552 — intervention group
Intervention type: OTHER
Intervention: Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
Description: Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
Study NCT05310591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
Description: Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks. It will include patients with MRD negative disease status.~1. Four decreasing starting times for beginning nivolumab (day 14, day 11, day 5 and day -1) will be available for testing~2. Patients will be enrolled sequentially by cohorts of 3 with escalation between cohorts based only on the limiting toxicities between infusion and D28~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response.
Study NCT05310591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab starting at day -1
Description: It will include relapsed patients. Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks.~-nivolumab starting at day -1.~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response.
Study NCT06516445 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: 5×5Gy，5Gy/d，QD，D1-D5
Study NCT06516445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, D1, ivgtt, Q3W, C1-4
Study NCT06516445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 100mg, BID, PO, Q3W, C1-4
Study NCT05124275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 1
Description: Pilocarpine Ophthalmic Topical Cream, Dose 1
Study NCT05124275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 2
Description: Pilocarpine Ophthalmic Topical Cream, Dose 2
Study NCT06516445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPEOX
Description: Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
Study NCT05124275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 3
Description: Pilocarpine Ophthalmic Topical Cream, Dose 3
Study NCT05124275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Topical Cream
Description: Placebo Ophthalmic Topical Cream
Study NCT06485115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Telerehabilitation (Euleria Home)
Description: After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the EG patients will perform the Digital Telerehabilitation program at home. The three weekly sessions will be asynchronous (with the caregiver's supervision if necessary). At each Unit, the physiotherapist will develop the training sessions on the Home- based Digital Telerehabilitation program and monitor the training execution provided by the digital device to adapt the rehabilitation treatment to the patients' improvements/difficulties. The Digital Telerehabilitation device (Euleria Home, Euleria Health) will consist of one wearable sensor and an app on a tablet that guides the patient through the customized exercise-therapy path configured by the professional. The sensor is worn on different body segments to monitor movements and provides real-time feedback on angles, balance, and repetitions.
Study NCT06485115 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy
Description: After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
Study NCT06485115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
Study NCT04761627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Participants will receive subcutaneous (SC) injection of ustekinumab.
Study NCT04761627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive subcutaneous (SC) injection of ustekinumab.
Study NCT04622995 — intervention group
Intervention type: DRUG
Intervention: Benzodiazepine
Description: Benzodiazepine prescribing
Study NCT04761627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 654
Description: Participants will receive SC injection of ABP 654.
Study NCT05203575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast-forwarding in Cycle 1
Description: The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks).
Study NCT06116851 — intervention group
Intervention type: OTHER
Intervention: MRI scan and laboratory visit
Description: Prostate MRI scan is performed according to the protocol used in earlier studies (PMID 31158230). In addition to the PCa diagnostics, the scan will include abdominal imaging to body composition analysis (visceral and subcutaneous fat and psoas muscle). Baseline blood and urine samples are collected in Turku University Hospital laboratory.
Study NCT06116851 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate biopsies
Description: The visit follows routine outpatient clinic protocol. The results from MRI and laboratory findings are discussed and the potential benefits and harms from prostate biopsies are evaluated. After a mutual decision, prostate biopsies are performed.
Study NCT06116851 — intervention group
Intervention type: PROCEDURE
Intervention: Radical prostatectomy and blood, urine and tissue sampling
Description: Baseline blood and urine samples are collected at the time of surgery. Robotic assisted laparoscopic prostatectomy (RALP) is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
Study NCT06116851 — intervention group
Intervention type: PROCEDURE
Intervention: TURP and blood, urine and tissue sampling
Description: Baseline blood and urine samples are collected the time of surgery. TURP is performed according to normal protocol. Routine diagnostic histopathological procedures will be followed in the department of pathology. Additionally, tissue samples (a total of 10 resection chips) will be collected for study analyses. Due to the study, no additional tissue samples are removed, i.e. study samples are from the tissues removed as clinically indicated.
Study NCT06116851 — intervention group
Intervention type: PROCEDURE
Intervention: Radical cystoprostatectomy and blood, urine and tissue sampling
Description: Baseline blood and urine samples are collected at the time of surgery. Radical cystoprostatectomy is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
Study NCT04831658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the dose-escalation phase
Description: The study adopts the 3+3 design,The dose planned to be explored is the daily oral dose of the BTK inhibitor abutinib, which is 100 mg, 150 mg and 200 mg, respectively.Orelabrutinib continues to be taken orally until the tumor is relieved for 3 months; PD-1 monoclonal antibody is used by intravenous drip, 21 days as a treatment cycle, and a total of 1 year of observation; formustine is used by intravenous drip for 21 days It is a treatment cycle, a total of 6 cycles of observation; after 2 cycles, the efficacy is evaluated, and adverse reactions are recorded. At the same time, MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times.
Study NCT05202405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221
Description: AD-221 Oral Tablet
Study NCT05202405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221A and AD-221B
Description: AD-221A Oral Tablet + AD-221B Oral Tablet
Study NCT04443829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR T-cells
Description: Infusion with: CD19CAR T-cells
Study NCT05679310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol/Essential oils
Description: A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
Study NCT06052124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Device
Description: AR device will be used to determine where to place SEPS drain
Study NCT06197126 — intervention group
Intervention type: RADIATION
Intervention: Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .
Description: The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
Study NCT05432570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A - Muscle Relaxants Used
Description: Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
Study NCT05432570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B - No Muscle Relaxants
Description: Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
Study NCT04910217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Patients will undergo conventional rehabilitation
Study NCT04910217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leg/lower body exerciser device intervention.
Description: Patients will undergo leg/lower body exerciser device therapy.
Study NCT04910217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lokomat intervention
Description: Patients will undergo therapy with Lokomat Pro FreeD device intervention.
Study NCT05203575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting plus Weekly Nudge in Cycle 1
Description: The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks).
Study NCT04512261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
Study NCT04512261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
Study NCT04512261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
Study NCT05480371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tracheal suctioning
Description: Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations.
Study NCT05480371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation/exsufflation
Description: Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
Study NCT04925323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: BLOOD SAMPLES
Study NCT04925323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: surgical tissue samples
Description: unused surgical tissue removed during plastic surgeries
Study NCT05463770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
Study NCT05667129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-101
Description: Capsule formulation
Study NCT05667129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule formulation
Study NCT05993169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Composition optimization visits
Description: Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
Study NCT05700838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cough Skill Training - with Variable Practice
Description: Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs.